Therefore, the concomitant participation of IFNα, BLyS and IL-17 in a pathogenic axis could be a key factor underlying the incomplete response to therapies based on the blockade of these cytokines in a subset of SLE patients. This evidence concerns the gene IFNA2 and systemic lupus erythematosus.